Orion Pharma and Qilu Pharma Europe agree biosimilar deal

Orion Oyj announced an agreement with Qilu Pharma Europe to commercialize an intravenous pembrolizumab biosimilar in Europe. Orion will gain exclusive rights to distribute, market, and sell Qilu's product.